DNA Probes Based Diagnostics Market to Reach US$ 31.9 Billion by 2030 | Abbott Laboratories, Beckman Coulter Inc, Becton Dickinson & Company

DNA Probes Based Diagnostics Market, having grown at a 4% CAGR from 2015 to 2019, is projected to reach US$ 31.9 billion by 2030, expanding at a CAGR of 5.1% from 2023 to 2030. Driven by rising demand for early and accurate diagnosis of infectious diseases, cancer, genetic predisposition, and forensic applications, DNA probe-based diagnostics are transforming healthcare with their high specificity and sensitivity. This press release explores the key drivers, projections, and opportunities shaping this dynamic industry.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=5474

Why Is the Market Expanding?

The increasing prevalence of infectious diseases, with 1.5 million annual cases of tuberculosis globally in 2024, drives demand for DNA probes to detect pathogens like Mycobacterium tuberculosis with 95% accuracy. The global cancer burden, projected to reach 30 million cases by 2030, fuels adoption for genetic mutation detection, such as BRCA1/2 for breast cancer, enabling 20% earlier interventions. Growing awareness of prenatal diagnostics, with 10% of expectant parents opting for genetic testing in 2024, supports genetic predisposition applications.

Forensic applications, including DNA profiling for criminal investigations, have risen by 15% due to advanced probe technologies like LGC Biosearch's BHQplex CoPrimers. Technological advancements, such as automated PCR systems, reduce costs by 12%, while global healthcare spending, reaching US$ 8.3 trillion in 2024, supports market growth. Challenges like high costs (US$ 500-2,000 per test) are mitigated by increasing automation and government funding for genomics, covering 25% of R&D costs.

What Are the Key Market Projections?

The market, valued at US$ 20.2 billion in 2023, is set to create an absolute dollar opportunity of US$ 11.7 billion by 2030, growing at a 5.1% CAGR to reach US$ 31.9 billion. The infectious diseases segment, holding a 40% share in 2023, is projected to grow at a 5.5% CAGR, generating US$ 4.8 billion in opportunities due to rising cases of HIV and hepatitis. Asia-Pacific, with a 35% share in 2023, leads with a 6.0% CAGR, driven by China's US$ 50 billion genomics investment and India's 12% rise in diagnostic labs. North America, growing at a 4.8% CAGR, benefits from 129,624 genetic tests available in the U.S. by 2022. Historical growth (2015-2019) at 4% reflects steady adoption, with acceleration expected due to precision medicine trends. Short-term growth (2023-2026) focuses on infectious diseases, while long-term trends (2027-2030) emphasize oncology and forensics.

How Can Stakeholders Capitalize on Opportunities?

Stakeholders in diagnostics, biotechnology, and forensics can leverage opportunities by investing in advanced probes, like Roche's 2024 fluorescent-labeled assays, improving detection speed by 15%. Partnerships, such as Thermo Fisher's 2023 collaboration with Asian hospitals, enhance market reach in Asia-Pacific, projected to account for 40% of demand by 2030. Focusing on cost-effective oligonucleotide probes, contributing 30% of revenue in 2023, ensures affordability. Compliance with FDA and EU MDR standards boosts market trust, while targeting high-growth markets like India, with a 7% CAGR, unlocks potential. Developing AI-integrated diagnostics, as piloted by Oxford Nanopore in 2024, enhances accuracy by 10%, addressing complex genomic data interpretation.

Browse Full Report: https://www.factmr.com/report/5474/dna-probes-based-diagnostics-market

What Does the Report Cover?

Fact.MR's report analyzes the DNA Probes Based Diagnostics Market across 30+ countries, covering segments by application (infectious diseases, cancer, genetic predisposition, identity/forensics, others) and region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa). It highlights trends like AI integration, point-of-care testing, and non-invasive diagnostics. Combining primary research from industry experts and secondary data, the report provides actionable insights into market dynamics, competitive strategies, and growth opportunities through 2030.

Who Are the Market Leaders?

Key players include Abbott Molecular, Beckman Coulter, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., and QIAGEN. Roche's 2023 acquisition of GenMark Diagnostics strengthened its infectious disease portfolio, while Abbott's 2024 BHQplus probes gained traction in oncology. These companies, holding over 50% of the market, drive innovation through R&D and mergers, such as Thermo Fisher's 2023 acquisition of Affymetrix. Regional players like bioMérieux focus on cost-effective solutions for Asia-Pacific, enhancing competitiveness. Strategic expansions, like QIAGEN's 2024 facility in China, bolster market presence.

What Are the Latest Market Developments?

In 2024, global infectious disease cases rose by 8%, boosting DNA probe demand for rapid diagnostics like HIV and TB testing. Asia-Pacific's 35% share reflects China's 15% increase in genomic research funding. Europe's growth, driven by a 10% rise in prenatal testing, aligns with the UK's NHS genomic initiatives. Innovations like Agilent's 2024 SureFISH probes improved cancer diagnostics by 12%. Forensic applications grew by 15%, supported by Promega's 2024 PowerPlex 18E System for complex sample analysis. Regulatory advancements, such as the EU's 2024 IVDR, increased adoption of compliant probes by 10%.

What Challenges and Solutions Exist?

High test costs (US$ 500-2,000) and regulatory hurdles, delaying approvals by 12 months, pose challenges. Limited skilled professionals, affecting 10% of labs, and complex data interpretation hinder growth. Solutions include automated platforms, reducing costs by 12%, and AI integration, improving data accuracy by 15%, as seen in SeqOne's 2024 collaboration with Oxford Nanopore. Localized production in Asia-Pacific, adopted by 20% of manufacturers, mitigates supply chain risks. Training programs, supported by 15% of U.S. institutions, address labor shortages. Compliance with ISO and FDA standards ensures market resilience.

Conclusion:

The Global DNA Probes Based Diagnostics Market is set to reach US$ 31.9 billion by 2030, driven by a 5.1% CAGR. With rising demand for infectious disease, cancer, and forensic diagnostics, coupled with technological advancements, the market offers transformative opportunities. Stakeholders can leverage Fact.MR's insights to target high-growth regions like Asia-Pacific, invest in AI-driven and cost-effective solutions, and address cost and regulatory challenges to thrive in this dynamic industry.

Check out More Related Studies Published by Fact.MR:

Blood Cancer Diagnostics Market: https://www.factmr.com/report/47/blood-cancer-diagnostics-market

Lung Cancer Diagnostics Market: https://www.factmr.com/report/49/lung-cancer-diagnostics-market

Ovarian Cancer Diagnostics Market: https://www.factmr.com/report/51/ovarian-cancer-diagnostics-market

Breast Cancer Diagnostics Market: https://www.factmr.com/report/55/breast-cancer-diagnostics-market

Kidney Cancer Diagnostics Market: https://www.factmr.com/report/56/kidney-cancer-diagnostics-market

Melanoma Cancer Diagnostics Market: https://www.factmr.com/report/57/melanoma-cancer-diagnostics-market

Cell-Free Fetal DNA Testing Market: https://www.factmr.com/report/2679/cell-free-fetal-dna-testing-market

Cell-free DNA Mutation Diagnostics Market: https://www.factmr.com/report/cell-free-dna-mutation-diagnostics-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.